about
Structural basis for recognition of CD20 by therapeutic antibody RituximabCrystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptideHumanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modellingDownregulation of ASPP2 improves hepatocellular carcinoma cells survival via promoting BECN1-dependent autophagy initiation.Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing.Preparation and characterization of recombinant protein ScFv(CD11c)-TRP2 for tumor therapy from inclusion bodies in Escherichia coli.Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU.Preparation and Characterization of Paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody.Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells.Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab.Development and characterization of a novel anti-IgE monoclonal antibody.Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMabThe protein-protein interface evolution acts in a similar way to antibody affinity maturation.The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors.Novel dual-control poly(N-isopropylacrylamide-co-chlorophyllin) nanogels for improving drug release.Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.Identification of a novel functional domain of ricin responsible for its potent toxicity.Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allograftsTolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.Osteopontin facilitates tumor metastasis by regulating epithelial-mesenchymal plasticityCharacterization and comparison of commercially available TNF receptor 2-Fc fusion protein productsPreclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Acid-induced aggregation propensity of nivolumab is dependent on the Fc.Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy.Antibody-targeted immunoliposomes for cancer treatment.Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles.The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes.Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.Development and characterization of a fully functional small anti-HER2 antibody.Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.Genetically targeted T cells eradicate established breast cancer in syngeneic mice.Development of SM5-1-conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection.Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
P50
Q27644280-0723920F-C673-4120-BFDD-01723ED26A98Q27650092-E6BD3A2E-7DED-4962-A3C6-B570FCB801D9Q28277157-429F83A5-C38F-4982-A79A-E7681ED7542CQ30008809-C7511F5E-A193-4573-80BF-992CD976ECF8Q30976158-314FA118-0CE1-4CD4-B736-6F481A295B91Q33259687-53DDA581-3893-430A-ADB3-ED8A6F560C8BQ33278735-50A8276A-729E-4313-855F-CEB563FB8801Q33302223-742EFB2A-D616-4452-B82F-03FEB123BA89Q33346360-55ABEC6A-1895-4B53-8E7B-C6A1696D22F0Q33362984-04A9A9A4-2214-4351-8E65-9240657AF3F7Q33556171-3ADFCB38-398B-44CE-8561-95962FF4ABF9Q33573605-38BDD8C7-AE7F-4D3A-9E9F-A28A17673308Q33662167-CBDF3242-1C7B-45E3-9FCD-FA2B8358C097Q33837886-F3CF5173-FC61-49C6-AF5D-7E680115ADEAQ34183165-5922D964-DB4B-49AB-B3B3-C098D9469048Q34570074-110EFA7F-5D32-4C99-96B1-B2469D289E8AQ34752125-45D12249-4FC7-45DD-94FC-5B79B4C06E7CQ35232365-3AF6D7A1-9CE8-4E84-B9F9-3283F23DDD60Q35918874-AFBB41CA-3802-4975-ADEE-7AE80C66C1F5Q36235346-BB1E099D-3778-42C0-9CF8-524555761C63Q36411858-8090E4CC-FAA6-4D94-9F35-D786F813968FQ37138420-1278D386-1D02-4D65-8FE0-572BE4142FF2Q37141601-FFCC1F49-C684-40DE-8E4B-154952880785Q37273477-2C564FAB-F425-4FD1-87C7-1E6C02622B90Q38087360-782AA078-F379-4BAB-BB51-B2B1059826B4Q38164096-35F6246B-85C7-4EEE-B267-A4C26E4467C1Q38743841-2347E8B1-3903-47C7-A406-02607658AFCDQ39357142-F6363072-F659-4C70-B5F3-2030195A42CCQ39597383-0F07379E-40F5-4DBC-BE97-AA988C764F5EQ39733175-D5A7CDDC-0776-4335-B68D-BCEA4BC37A33Q39782019-86B1E510-A8C2-466C-9F5F-29D7932B570DQ39787467-D979385C-30E8-44A8-9867-FF3A053BD46EQ39810957-7CBE7F19-F9FB-4E3A-B30B-003070F15F8EQ39827951-A01FAFF0-D2FF-429A-A320-80A84E916123Q39850649-2496A9B4-9CED-456E-8DF0-6448947A92A6Q39888332-EAF0F94F-67AB-492C-8C89-750374896CA9Q39962261-50B2C197-9C33-4863-A964-FDF71858E0BBQ39981867-9D7912E4-9C0A-41E0-8AFB-C5C9716BBE61Q39982179-184BB728-2EEE-40BE-90F7-09518B48F495Q39996218-C69D5296-8B3A-418F-98B1-EF237FB2B952
P50
name
Bohua Li
@en
Bohua Li
@nl
type
label
Bohua Li
@en
Bohua Li
@nl
prefLabel
Bohua Li
@en
Bohua Li
@nl